Fernanda Pacella, Adriana Francesca Ferraresi, Paolo Turchetti, Tommaso Lenzi, Rosalia Giustolisi, Andrea Bottone, Valeria Fameli, Maria Rosaria Romano, Elena Pacella
{"title":"玻璃体内注射Ozurdex(®)植体治疗持续性糖尿病黄斑水肿患者，随访6个月。","authors":"Fernanda Pacella, Adriana Francesca Ferraresi, Paolo Turchetti, Tommaso Lenzi, Rosalia Giustolisi, Andrea Bottone, Valeria Fameli, Maria Rosaria Romano, Elena Pacella","doi":"10.4137/OED.S38028","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the efficacy of intravitreal dexamethasone injections in diabetic macular edema (DME).</p><p><strong>Methods: </strong>A 700 μg slow-release intravitreal dexamethasone implant (Ozurdex®) was placed in the vitreal cavity of 17 patients (19 eyes) affected with persistent DME. Best corrected visual acuity (BCVA) was assessed through Early Treatment Diabetic Retinopathy Study (ETDRS). Central macular thickness (CMT) was measured by spectral-domain optical coherence tomography. BCVA and CMT examinations were carried out at baseline (T0) and repeated after three days, one month (T1), three months (T3), four months (T4), and six months (T6) post injection.</p><p><strong>Results: </strong>Dexamethasone implant induced an improvement in ETDRS at T1, T3, T4, and T6 post injection. CMT was reduced at T1, T3, and T4, while at T6, CMT values were not statistically different from baseline. No complications were observed during the follow-up.</p><p><strong>Conclusion: </strong>Our data suggest that dexamethasone implant is effective in reducing DME symptoms within a six-month frame.</p>","PeriodicalId":74362,"journal":{"name":"Ophthalmology and eye diseases","volume":"8 ","pages":"11-6"},"PeriodicalIF":0.0000,"publicationDate":"2016-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/OED.S38028","citationCount":"48","resultStr":"{\"title\":\"Intravitreal Injection of Ozurdex(®) Implant in Patients with Persistent Diabetic Macular Edema, with Six-Month Follow-Up.\",\"authors\":\"Fernanda Pacella, Adriana Francesca Ferraresi, Paolo Turchetti, Tommaso Lenzi, Rosalia Giustolisi, Andrea Bottone, Valeria Fameli, Maria Rosaria Romano, Elena Pacella\",\"doi\":\"10.4137/OED.S38028\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>To evaluate the efficacy of intravitreal dexamethasone injections in diabetic macular edema (DME).</p><p><strong>Methods: </strong>A 700 μg slow-release intravitreal dexamethasone implant (Ozurdex®) was placed in the vitreal cavity of 17 patients (19 eyes) affected with persistent DME. Best corrected visual acuity (BCVA) was assessed through Early Treatment Diabetic Retinopathy Study (ETDRS). Central macular thickness (CMT) was measured by spectral-domain optical coherence tomography. BCVA and CMT examinations were carried out at baseline (T0) and repeated after three days, one month (T1), three months (T3), four months (T4), and six months (T6) post injection.</p><p><strong>Results: </strong>Dexamethasone implant induced an improvement in ETDRS at T1, T3, T4, and T6 post injection. CMT was reduced at T1, T3, and T4, while at T6, CMT values were not statistically different from baseline. No complications were observed during the follow-up.</p><p><strong>Conclusion: </strong>Our data suggest that dexamethasone implant is effective in reducing DME symptoms within a six-month frame.</p>\",\"PeriodicalId\":74362,\"journal\":{\"name\":\"Ophthalmology and eye diseases\",\"volume\":\"8 \",\"pages\":\"11-6\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-04-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.4137/OED.S38028\",\"citationCount\":\"48\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ophthalmology and eye diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4137/OED.S38028\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2016/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology and eye diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4137/OED.S38028","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2016/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
Intravitreal Injection of Ozurdex(®) Implant in Patients with Persistent Diabetic Macular Edema, with Six-Month Follow-Up.
Aim: To evaluate the efficacy of intravitreal dexamethasone injections in diabetic macular edema (DME).
Methods: A 700 μg slow-release intravitreal dexamethasone implant (Ozurdex®) was placed in the vitreal cavity of 17 patients (19 eyes) affected with persistent DME. Best corrected visual acuity (BCVA) was assessed through Early Treatment Diabetic Retinopathy Study (ETDRS). Central macular thickness (CMT) was measured by spectral-domain optical coherence tomography. BCVA and CMT examinations were carried out at baseline (T0) and repeated after three days, one month (T1), three months (T3), four months (T4), and six months (T6) post injection.
Results: Dexamethasone implant induced an improvement in ETDRS at T1, T3, T4, and T6 post injection. CMT was reduced at T1, T3, and T4, while at T6, CMT values were not statistically different from baseline. No complications were observed during the follow-up.
Conclusion: Our data suggest that dexamethasone implant is effective in reducing DME symptoms within a six-month frame.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
